FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 331:489-495 August 25, 1994 Number 8 Next

Abstract Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Balloon-expandable coronary-artery stents were developed to prevent coronary restenosis after coronary angioplasty. These devices hold coronary vessels open at sites that have been dilated. However, it is unknown whether stenting improves long-term angiographic and clinical outcomes as compared with standard balloon angioplasty.

Methods A total of 520 patients with stable angina and a single coronary-artery lesion were randomly assigned to either stent implantation (262 patients) or standard balloon angioplasty (258 patients). The primary clinical end points were death, the occurrence of a cerebrovascular accident, myocardial infarction, the need for coronary-artery bypass surgery, or a second percutaneous intervention involving the previously treated lesion, either at the time of the initial procedure or during the subsequent seven months. The primary angiographic end point was the minimal luminal diameter at follow-up, as determined by quantitative coronary angiography.

Results After exclusions, 52 patients in the stent group (20 percent) and 76 patients in the angioplasty group (30 percent) reached a primary clinical end point (relative risk, 0.68; 95 percent confidence interval, 0.50 to 0.92; P = 0.02). The difference in clinical-event rates was explained mainly by a reduced need for a second coronary angioplasty in the stent group (relative risk, 0.58; 95 percent confidence interval, 0.40 to 0.85; P = 0.005). The mean (±SD) minimal luminal diameters immediately after the procedure were 2.48 ±0.39 mm in the stent group and 2.05 ±0.33 mm in the angioplasty group; at follow-up, the diameters were 1.82 ±0.64 mm in the stent group and 1.73 ±0.55 mm in the angioplasty group (P = 0.09), which correspond to rates of restenosis (diameter of stenosis, 50 percent) of 22 and 32 percent, respectively (P = 0.02). Peripheral vascular complications necessitating surgery, blood transfusion, or both were more frequent after stenting than after balloon angioplasty (13.5 vs. 3.1 percent, P<0.001). The mean hospital stay was significantly longer in the stent group than in the angioplasty group (8.5 vs. 3.1 days, P<0.001).

Conclusions Over seven months of follow-up, the clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty. However, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.

Methods

Selection of Patients

Patients scheduled to undergo coronary angioplasty because of stable angina due to a single new lesion in a coronary artery were eligible for the study if they had no contraindication to anticoagulant or antiplatelet therapy and if they were also suitable candidates for coronary bypass surgery. The target lesion needed to be less than 15 mm long and to be located in a vessel more than 3 mm in diameter that supplied normally functioning myocardium. Patients with an ostial lesion, a lesion at a bifurcation, or a lesion in a previously grafted vessel were excluded from the study, as were patients in whom an intracoronary thrombus was suspected.

The study was carried out according to the principles of the Declaration of Helsinki. Oral or written informed consent according to local practice was obtained for every patient.

Randomization

Patients were randomly assigned by telephone from a central office to either implantation of a Palmaz-Schatz stent or balloon angioplasty. To ensure an equal distribution of treatments in each center, we developed the randomization sequence on a site basis in blocks of six treatment assignments.

Balloon Angioplasty and Stent Implantation

Balloon angioplasty and stent implantation were performed according to standard clinical practice by the femoral approach. The stent was deployed by inflating a balloon over which the collapsed stent was fitted. Inflation of the balloon expanded the stent. After the implantation of the stent, the stented area was often dilated further by standard balloon angioplasty. All patients received 250 to 500 mg of aspirin daily and 75 mg of dipyridamole three times a day; this treatment was started the day before the procedure and was continued for six months. During the procedure, patients receiving a stent were treated with a continuous infusion of dextran (1000 ml) and a bolus dose of 10,000 U of heparin, repeated if necessary, followed by a combination of heparin and oral anticoagulation therapy (with warfarin) after the removal of the sheath and titrated by measuring the prothrombin time and either the activated partial-thromboplastin time or the activated clotting time. The dose of heparin was decreased progressively after the prothrombin time had been in the therapeutic range (international normalized ratio, 2.5 to 3.5) for at least 36 hours. Warfarin therapy was continued for three months. The patients who underwent balloon angioplasty received only 10,000 U of heparin during that procedure, followed by an additional bolus dose or a continuous infusion if deemed necessary. In addition, both treatment groups received calcium antagonists until discharge from the hospital.

Clinical and Angiographic Follow-up

Patients were seen in the outpatient clinic after one, three, and six months for an interview, physical examination, and electrocardiogram. Exercise testing was performed before the second cardiac catheterization and coronary angiography at six months. If a revascularization procedure involving the treated segment had been performed before the six-month angiography, the most recent angiogram obtained before this intervention, if available, was used as the follow-up angiogram, regardless of the timing of the second intervention. If the time to follow-up angiography was less than three months and no second intervention was performed, the patient was asked to undergo angiography again at six months. In the absence of a second angiogram at six months, the angiogram obtained most recently within the previous three months was used, if available, provided that no end point had occurred.

Three angiograms were obtained for each patient -- one just before the intervention, one immediately after, and one at follow-up. All the angiograms were analyzed by the Cardiovascular Angiography Analysis System and sent to the core laboratory (Cardialysis, Rotterdam, the Netherlands). To standardize the method of data acquisition and to ensure the exact reproducibility of the angiograms performed after the intervention and at follow-up, measurements were made as described earlier⁸.

End Points

The primary clinical end points were whichever of the following occurred first: death, a cerebrovascular accident, myocardial infarction, bypass surgery, or a second percutaneous intervention involving the previously treated lesion between the time of the initial procedure and the angiography performed at 6 months (±4 weeks) (or at 7 months if no angiography was performed at 6 months). The indication for a second intervention or for bypass surgery had to be substantiated by symptoms or by electrocardiographic or scintigraphic evidence of myocardial ischemia at rest or during exercise. All events were reviewed by the critical-event committee, which was unaware of the treatment assignments.

Death was defined to include all deaths, regardless of cause. Cerebrovascular accidents occurring in patients receiving anticoagulant therapy were considered to be intracranial hemorrhages unless unequivocally demonstrated otherwise. Myocardial infarction was diagnosed if there were new pathologic Q waves according to the Minnesota Code⁹ or if there was an increase in serum creatine kinase to more than twice the normal value, together with a pathologic increase in myocardial isoenzymes. Bypass surgery was defined to include emergency or elective bypass surgery involving the previously treated segment. Emergency bypass surgery was defined as involving an immediate transfer from the angioplasty suite to the operating room during the initial phase of treatment. "Bailout" stent implantation was defined as the placement of a stent in the event of Thrombolysis in Myocardial Infarction (TIMI) grade 0 or 1 flow after angioplasty or in the case of worsening of the base-line TIMI flow by one grade¹⁰. In all instances, prolonged balloon angioplasty had to be attempted before bailout stenting was considered. By design, stent implantation as a bailout procedure was considered equivalent to emergency bypass surgery but was removed retroactively from the analysis of primary end points, since it is currently perceived as an integral part of an angioplasty strategy. Only the untoward clinical events associated with such stenting were counted as end points. Second interventions were those involving a previously treated lesion that followed the initial procedure, which was considered complete when the guiding catheter was removed from the arterial sheath. Revascularization (surgical or percutaneous) involving other coronary arteries did not constitute an end point.

The primary angiographic end point was the minimal luminal diameter at follow-up. For each treated segment, this value was calculated from the mean values obtained in multiple matched projections.

Secondary end points included (1) the angiographic success rate, defined as the rate of achievement of less than 50 percent stenosis on visual assessment; (2) the procedural success rate, defined as the rate of achievement of less than 50 percent stenosis on quantitative assessment, without the occurrence of clinical events during the hospital stay; (3) the functional class according to the classification of the Canadian Cardiovascular Society at six months or at the time of intercurrent angiography and second intervention; (4) the results of exercise testing at six months or earlier, if clinically indicated; (5) the rate of restenosis (stenosis 50 percent at follow-up) at six months.

Power Calculations and Statistical Analysis

At the outset of the study, the size of the required sample (428 patients) was based on an assumed rate of clinical events of 30 percent in the angioplasty group and a reduction of that rate by 40 percent in the stent group (by a two-sided test with an alpha error of 0.05 and a power of 0.80). To compensate for unsuccessful interventions and losses to follow-up, the sample was enlarged by 10 percent (to 470 patients). In addition, to adjust for a loss of power due to a planned interim analysis, the sample was increased by another 10 percent, reaching a final size of 520 patients¹¹.

The main clinical analysis consisted of a single comparison between the two study groups with respect to the primary clinical end point, regardless of its time of occurrence; this analysis involved all randomized patients with the exceptions of three patients found after randomization not to be eligible and of one patient who withdrew informed consent for further treatment and follow-up according to the intention-to-treat principle. The clinical events were ranked according to the highest category of severity on the following scale: death, cerebrovascular accident, myocardial infarction, emergency bypass surgery, elective bypass surgery, and repeat percutaneous intervention.

The main angiographic analysis consisted of a single comparison between the two study groups with respect to minimal luminal diameter and was performed according to the intention-to-treat principle.

Continuous variables are expressed as means ±SD and were compared by the unpaired Student's t-test. The chi-square test with Yates' correction was used to compare proportions. Discrete variables are expressed as counts and percentages and are compared in terms of relative risks (for stenting as compared with angioplasty), with 95 percent confidence intervals calculated by the formula of Greenland and Robins¹². All statistical tests were two-tailed.

Results

Characteristics of the Patients

Between June 1991 and March 1993, 520 patients were randomly assigned to stent implantation (262 patients) or balloon angioplasty (258 patients) at 28 participating centers. Of these 520 patients, 4 were excluded from further analysis, 3 in the stent group and 1 in the angioplasty group. One patient withdrew his informed consent and left the hospital without receiving treatment, two other patients did not undergo coronary revascularization because their lesions proved to be unimportant during on-line quantitative coronary angiography at the time of the intended intervention, and one patient participated in another study with an investigational drug. There were no differences in base-line characteristics between the two study groups (Table 1 and Table 2).

View this table: [in this window] [in a new window]   Table 1. Base-Line Clinical Characteristics of the 516 Patients Included in the Intention-to-Treat Analysis.

 

View this table: [in this window] [in a new window]   Table 2. Angiographic Characteristics of the 516 Patients Included in the Intention-to-Treat Analysis and Characteristics of the Procedures They Underwent.

 
In-Hospital Clinical Outcomes

Of the remaining 259 patients randomly assigned to receive stents, 14 (5.4 percent) did not receive a stent but were treated successfully with balloon angioplasty. The reasons for this crossover were the withdrawal of informed consent in five, the physician's preference because of the patient's unfavorable anatomy (e.g., small vessel size) or angiographic evidence of thrombus in three, and failure to cross the lesion with the stent in six. In addition, stent implantation was unsuccessful in 10 patients: 6 because the lesion was not dilated beforehand and 4 because the stent could not be deployed. Of these 10 patients, 8 underwent bypass surgery that was urgent in 3 and elective in 5. The remaining two patients, who unexpectedly had totally occluded coronary arteries that could not be recanalized, were treated medically.

Of the 257 remaining patients randomly assigned to balloon angioplasty, 13 (5.1 percent) received stents for the following reasons: acute vessel closure in 1, flow-limiting dissection in 11, and a suboptimal angiographic result in 1. Of these 13 patients, 2 were referred for urgent bypass surgery and 1 had a non-Q-wave myocardial infarction. In addition, three other patients who had complicated balloon angioplasty and in whom no bailout stent implantation was attempted underwent urgent bypass surgery. Therefore, the angiographic success rate was 96.9 percent in the stent group and 98.1 percent in the angioplasty group, whereas the procedural success rates were 92.7 and 91.1 percent, respectively.

The ranking and the total number of clinical events occurring in the hospital are shown in Table 3. The composite rate for all in-hospital events was similar in both groups (16 events or 6.2 percent in the angioplasty group vs. 18 events or 6.9 percent in the stent group; relative risk, 1.12; 95 percent confidence interval, 0.58 to 2.14). There were no in-hospital deaths in either group; one patient treated with balloon angioplasty had an intracranial hemorrhage. There was no difference between groups in the incidence of Q-wave and non-Q-wave infarction (3.1 percent in the angioplasty group vs. 3.4 percent in the stent group; relative risk, 1.12; 95 percent confidence interval, 0.44 to 2.85) or in the need for urgent or elective cardiac surgery or second angioplasty during the hospital stay (2.7 percent in the angioplasty group vs. 3.5 percent in the stent group; relative risk, 1.28; 95 percent confidence interval, 0.48 to 3.37).

View this table: [in this window] [in a new window]   Table 3. Frequency of Primary Clinical End Points in the Hospital and at Seven Months in Descending Order of Severity, Total Number of Events, and Quantitative Comparison of Immediate and Long-Term Angiographic Results.

 
Angiographically documented stent thrombosis during the hospital stay occurred in 3.5 percent of patients, an incidence similar to that of subacute vessel closure after balloon angioplasty (2.7 percent). It is noteworthy that no stent thrombosis occurred in the 13 patients treated with a bailout stent. However, the incidence of bleeding and vascular complications was significantly higher after stent implantation than after balloon angioplasty (13.5 vs. 3.1 percent; relative risk, 4.34; 95 percent confidence interval, 2.05 to 9.18; P<0.001).

The mean hospital stay was 8.5 days in the stent group and 3.1 days in the angioplasty group (P<0.001).

Clinical Outcomes at Seven Months

The numbers of various types of clinical events at seven months among all 516 patients are shown in Table 3. A primary clinical end point was reached by 76 of the 257 patients randomly assigned to balloon angioplasty (30 percent), as compared with 52 of the 259 patients randomly assigned to stent implantation (20 percent) (relative risk, 0.68; 95 percent confidence interval, 0.50 to 0.92; P = 0.02). This difference in long-term clinical outcome is shown in the cumulative distribution curves for the primary clinical end point in both treatment groups (Figure 1D). The favorable long-term outcome in the stent group was also partly reflected in the difference between the two groups in functional class at the time of the second angiography (Table 4). The most striking difference in clinical outcomes was the significantly reduced need for an elective second revascularization by means of percutaneous intervention involving the target lesion. There was a 42 percent reduction favoring stent implantation.

View larger version (22K): [in this window] [in a new window]   Figure 1. Cumulative Frequency Distribution Curves for the Two Study Groups, Showing Minimal Luminal Diameters Measured before and after Intervention and at Follow-up, the Percentage of Stenosis at Follow-up, and the Percentage of Patients with Clinical End Points. Significant differences were apparent that consistently favored the stent group over the angioplasty group with respect to the increased minimal luminal diameter at intervention (Panel A) and follow-up (Panel B), the percentage of stenosis at follow-up (Panel C), and the incidence of major clinical events (Panel D). The vertical dashed line in Panel D indicates the end of the study.

 

View this table: [in this window] [in a new window]   Table 4. Functional Class at Seven Months of Follow-up or at the Time of the Intercurrent Intervention for the 516 Patients Included in the Intention-to-Treat Analysis.

 
During the study, three patients died, one in the angioplasty group and two in the stent group. One patient treated with balloon angioplasty committed suicide four months after the intervention. Two other patients died two and three weeks after successful stent implantations. In the first of these patients, death was preceded by chest pain associated with ST-segment elevation and was therefore thought to be related to a subacute occlusion. In the second patient, the cause of death was hypovolemic shock during surgical repair of an arteriovenous fistula. Although the stent was patent at the time of the pathological examination, the death was considered to be related to the stent.

Angiographic Analysis

Angiographic follow-up data were obtained for 93 percent of the eligible patients (Table 3). The minimal luminal diameter at follow-up was greater after stent implantation than after balloon angioplasty (1.82 ±0.64 vs. 1.73 ±0.55 mm, P = 0.09; median difference, 0.17 mm). The cumulative distribution of the minimal luminal diameter and percentage of stenosis are shown in Figure 1A, Figure B, and Figure C. The incidence of restenosis (the criterion for which was 50 percent stenosis) was 22 percent after stent implantation as compared with 32 percent after balloon angioplasty (P = 0.02).

Discussion

We found that implantation of coronary stents in patients with stable angina and a single new coronary-artery lesion was associated with a rate of immediate clinical success similar to that of standard balloon angioplasty, but a significantly lower rate of restenosis. This translated into a superior long-term clinical outcome, mainly due to a reduced need for additional percutaneous intervention, at least according to the composite analysis of clinical end points. The advantage of this combined clinical end point is that it leads to a simple estimate of the effect of treatment. However, this analysis ignores the relative effect of various events (i.e., it considers death, a cerebrovascular accident, myocardial infarction, and the like to be equally harmful to the patient) and does not reflect the multiplicity of events that may occur (e.g., in a patient undergoing second angioplasty and surgery and ultimately dying). To address this shortcoming, a count of all events is included in Table 3.

One of the major drawbacks of studies on the prevention of coronary restenosis is that at follow-up the angiographic knowledge of coronary anatomy may influence the physician's therapeutic decision and artificially increase the number of second interventions. This is especially true when the investigator is not kept unaware of the treatment assignments, as when a new device is tested. To circumvent this possible source of bias, a second intervention was considered an end point in this study only when it was substantiated on the basis of anginal symptoms or objective evidence of ischemia (Table 5). Only two second interventions in the angioplasty group and one in the stent group might not have been justified. Moreover, the fact that the cumulative curves for the composite clinical end points (Figure 1D) diverged between day 75 and day 150 indicates that the difference in clinical outcome was not artificially driven by the angiographic findings at the time of the second catheterization.

View this table: [in this window] [in a new window]   Table 5. Presence of Clinical Symptoms, Ischemic Signs, and Degree of Stenosis in Patients Who Underwent a Second Intervention at Follow-up.

 
Not unexpectedly, the incidence of major bleeding complications was significantly higher in the stent group (13.5 percent) than in the angioplasty group (3.1 percent). The overall incidence reported in the literature, expressed as a weighted average of groin hematomas and pseudoaneurysms, was 7.5 percent (range, 2.7 to 26 percent) and 4.2 percent (range, 0 to 10.8 percent), respectively¹⁷.

Another significant difference between the two treatment groups was in the duration of hospitalization. However, Cohen et al. recently showed that length of stay, consumption of resources, and total costs were still substantially greater for bypass surgery than for stenting and that the initially higher in-hospital costs of stent implantation as compared with balloon angioplasty are compensated for by the reduction in subsequent interventions during follow-up^18,19. The practitioner and the patient must, however, weigh a long hospital stay and a 13.5 percent risk of bleeding and vascular complications against the potential benefit of a reduction in the likelihood of clinical events from 30 percent to 20 percent.

It may be argued that the difference in drug therapy between the two study groups accounts for the observed differences in angiographic outcome and rate of restenosis. However, a number of clinical studies collectively rule out any beneficial effect of anticoagulant therapy on restenosis in humans^{20,21,22,23,24,25}. Moreover, the degree of angiographically documented luminal loss was significantly higher after stent implantation than after balloon angioplasty (Table 3). Therefore, the beneficial angiographic and clinical effects of stent implantation are explained by the propensity of the stent to achieve a consistently greater increase in luminal diameter immediately after the procedure than is the case with balloon angioplasty, which is inherently limited by the well-described phenomenon of elastic recoil^3,26.

It should be emphasized that in interpreting the favorable results observed in this trial, the restrictive nature of the criteria for inclusion and exclusion must be kept in mind, and thus the results may not be generalizable to other patients, indications, and types of stents. Finally, bleeding and vascular complications and the prolonged hospitalization remain major drawbacks of stent implantation and continue to hamper its acceptance in clinical practice.

Supported in part by a grant from Johnson and Johnson Interventional Systems, Warren, N.J.; Schneider and Co., Bulach, Switzerland; and Lorex Pharmaceutica BV, Maarssen, the Netherlands.

Source Information

From the University Hospital Rotterdam Dijkzigt, Thorax Center, Rotterdam, the Netherlands (P.W.S., P.J., M.A.M.); Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (F.K.); University Hospital San Carlos, Madrid, Spain (C.M.); Universitatsklinikum Rudolf Virchow, Charlottenburg, Berlin, Germany (W.R.); Onze Lieve Vrouwe Kliniek, Aalst, Belgium (G.H.); Sahlgrenska Hospital, Goteborg, Sweden (H.E.); Clinique Pasteur, Toulouse, France (J.M.); Sart-Tilman Centre Hospitalier Universitaire, Liege, Belgium (V.L.); Hopital de la Citadelle, Liege, Belgium (P.M.); Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina (J.B.); Royal Brompton National Heart and Lung Institute, London (U.S.); Centro Cuore Columbus, Milan, Italy (A.C.); Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (J.J.G.); Middelheim Ziekenhuis, Antwerp, Belgium (P.H.); and Gregorio Maranon, Madrid, Spain (J.D.). The remaining investigators in the Benestent Study Group are listed in the Appendix.

Address reprint requests to Dr. Serruys at the Catheterization Laboratory, Thorax Center, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands.

References

1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706. [Abstract]
2. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927. [Free Full Text]
3. de Jaegere PPT, Hermans WR, Rensing BJ, Strauss BH, de Feyter PJ, Serruys PW. Matching based on quantitative coronary angioplasty as a surrogate for randomized studies: comparison between stent implantation and balloon angioplasty of native coronary artery lesions. Am Heart J 1993;125:310-319. [CrossRef][Medline]
4. Fischman DL, Savage MP, Ellis SG, et al. Restenosis after Palmaz-Schatz stent implantation. In: Serruys PW, Strauss BH, King SB III, eds. Restenosis after intervention with new mechanical devices. Vol. 131 of Developments in cardiovascular medicine. Dordrecht, the Netherlands: Kluwer Academic, 1992:191-205.
5. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent: initial results of a multicenter study. Circulation 1991;83:148-161. [Free Full Text]
6. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13-17. [Abstract]
7. de Jaegere PPT, de Feyter PJ, van der Giessen WJ, Serruys PW. Endovascular stents: preliminary clinical results and future developments. Clin Cardiol 1993;16:369-378. [Medline]
8. Serruys PW, Foley DP, de Feyter PJ, eds. Quantitative coronary angiography in clinical practice. Dordrecht, the Netherlands: Kluwer Academic, 1994.
9. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation 1960;21:1160-1175. [Free Full Text]
10. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase 1 findings. N Engl J Med 1985;312:932-936. [Medline]
11. Pocock SJ. Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 1982;38:153-162. [CrossRef][Medline]
12. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68. [CrossRef][Medline]
13. Hermans WRM, Rensing BJ, Foley DP, et al. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. J Am Coll Cardiol 1992;20:767-780. [Abstract]
14. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609-616. [Abstract]
15. Ellis SG, Roubin GS, King SB III, Douglas JS Jr, Cox WR. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol 1989;63:30-34. [CrossRef][Medline]
16. Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation 1983;67:723-730. [Free Full Text]
17. de Jaegere P, de Feyter P, Serruys PW. Intracoronary stenting. Curr Rev Interv Cardiol 1993;8:1-17.
18. Cohen DJ, Breall JA, Ho KK, et al. Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol 1993;22:1052-1059. [Abstract]
19. Cohen DJ, Breall JA, Ho KK, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model. Circulation 1994;89:1859-1874. [Free Full Text]
20. Hirshfeld JW, Schwartz SS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18:647-656. [Abstract]
21. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782. [CrossRef][Medline]
22. Perin EC, Turner SA, Ferguson JJ. Relationship between the response to heparin and restenosis following PTCA. Circulation 1990;82:Suppl III:III-497.abstract 
23. Faxon D, Spiro T, Minor S, et al. Enoxaparin, a low molecular weight heparin, in the prevention of restenosis after angioplasty: result of a double blind randomized trial. J Am Coll Cardiol 1992;19:Suppl A:258A-258A.abstract 
24. Thornton MA, Gruentzig AR, Hollman J, King SB III, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984;69:721-727. [Free Full Text]
25. Urban P, Buller N, Fox K, Shapiro L, Bayliss J, Rickards A. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Br Heart J 1988;60:485-488. [Free Full Text]
26. Rensing BJ, Hermans WR, Beatt KJ, et al. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;66:1039-1044. [CrossRef][Medline]

The following institutions and investigators participated in the Benestent study. The number of patients enrolled at each center is given in parentheses.

University Hospital San Carlos, Madrid, Spain (76): F. Alfonso, J. Goicolea, R. Hernandez, and A. Iniguez; University Hospital Rotterdam Dijkzigt, Thorax Center, Rotterdam, the Netherlands (57): P.J. de Feyter and M. van den Brand; Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (50): G.J. Laarman and R. vander Wieken; Universitatsklinikum Rudolf Virchow, Charlottenburg, Berlin, Germany (39): W. Rutsch; Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium (38): B. de Bruyne; Sahlgrenska Hospital, Goteborg, Sweden (36): P. Albertsson; Clinique Pasteur, Toulouse, France (32): J. Fajadet, S. Doucet, and O. Bar; Sart-Tilman Centre Hospitalier Universitaire, Liege, Belgium (32): V. Legrand; Hopital de la Citadelle, Liege, Belgium (19): J. Boland; Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina (19): J. Berrocal and R. Piraino; Royal Brompton National Heart and Lung Institute, London (12): N. Buller and K. Priestley; Centro Cuore Columbus, Milan, Italy (11): L. Maiello; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (11): E. Eeckhout; Middelheim Ziekenhuis, Antwerp, Belgium (10): F. van den Brande; Gregorio Maranon, Madrid, Spain (10): E. Garcia; Ziekenhuis de Weezenlanden, Zwolle, the Netherlands (8): H. Suryapranata and J. Hoorntje; St. Antonius Ziekenhuis, Nieuwegein, the Netherlands (8): T. Plokker and G. Mast; Hospital Maggiore, Trieste, Italy (8): S. Klugmann, E. Della Grazia, and A. Salvi; Hopital Cantonal Universitaire, Geneva, Switzerland (7): P. Urban and E. Camenzind; Academisch Ziekenhuis Groningen, Groningen, the Netherlands (6): P. den Heijer and R. van Dijk; Academic Medical Center, Amsterdam, the Netherlands (6): J. Piek and K. Koch; Christian Albrechts University, Kiel, Germany (6): R. Simon and G. Herrmann; Centre Cardiologique du Nord, Paris (5): M.C. Morice and T. Royer; St. James Hospital, Dublin, Ireland (5): P. Crean; Catharina Ziekenhuis, Eindhoven, the Netherlands (3): H. Bonnier, J. Koolen, and F. Bracke; Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Brussels, Belgium (2): W. Wijns; Centre Hospitalier Regional et Universitaire, Nancy, France (2): N. Danchin and Y. Juilliere; and the Polyclinique Volney, Rennes, France (2): C. Bourdonnec.

Ethics and Safety Committee: F. Verheugt, Free University Amsterdam, Amsterdam, the Netherlands; J. Tijssen, Academic Medical Center, Amsterdam, the Netherlands; and G. de Backer, State University Ghent, Ghent, Belgium.

Steering Committee: P.W. Serruys (chairman), H. Emanuelsson, G.R. Heyndrickx, P.P.T. de Jaegere, F. Kiemeneij (co-chairman), C. Macaya, J. Marco, and P. Materne.

Critical Event Committee: F. Kiemeneij (chairman), P.W. Serruys, P.P.T. de Jaegere, P.J. de Feyter, and P. van den Heuvel.

Angiographic Assessment Committee: P.P.T. de Jaegere (chairman), P.W. Serruys, W. Rutsch, B. de Bruyne, and V. Legrand.

Exercise Testing Committee: V. Legrand (chairman), G. Laarman, and N. Danchin.

Data Coordinating and Analysis Center and Quantitative Angiographic Core Laboratory: Cardialysis, Rotterdam, the Netherlands: M. Morel, A.G. Azar, G.A. van Es, J.P. Herrman, R. Melkert, J. Pameyer, and L.M. Rodenburg.

Abstract Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Coronary-Stent Placement Compared with Balloon Angioplasty
Bittl J. A., Schwartz L., Serruys P. W., The Benestent Investigators , Fischman D. L., Savage M. P., Goldberg S., Topol E. J.
Extract | Full Text  
N Engl J Med 1995; 332:536-538, Feb 23, 1995. Correspondence

This article has been cited by other articles:

• Silber, S., Colombo, A., Banning, A. P., Hauptmann, K., Drzewiecki, J., Grube, E., Dudek, D., Baim, D. S. (2009). Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions. Circulation 120: 1498-1504 [Abstract] [Full Text]  
• Gulati, R., Rihal, C. S., Gersh, B. J. (2009). The SYNTAX Trial: A Perspective. Circ Cardiovasc Interv 2: 463-467 [Full Text]  
• Lagerqvist, B., Carlsson, J., Frobert, O., Lindback, J., Schersten, F., Stenestrand, U., James, S. K., for the Swedish Coronary Angiography and Angioplas, (2009). Stent Thrombosis in Sweden: A Report From the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2: 401-408 [Abstract] [Full Text]  
• Waksman, R., Pakala, R. (2009). Drug-Eluting Balloon: The Comeback Kid?. Circ Cardiovasc Interv 2: 352-358 [Full Text]  
• Yokoyama, S., Takano, M., Yamamoto, M., Inami, S., Sakai, S., Okamatsu, K., Okuni, S., Seimiya, K., Murakami, D., Ohba, T., Uemura, R., Seino, Y., Hata, N., Mizuno, K. (2009). Extended Follow-Up by Serial Angioscopic Observation for Bare-Metal Stents in Native Coronary Arteries: From Healing Response to Atherosclerotic Transformation of Neointima. Circ Cardiovasc Interv 2: 205-212 [Abstract] [Full Text]  
• Nakazawa, G., Vorpahl, M., Finn, A. V., Narula, J., Virmani, R. (2009). One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.. J Am Coll Cardiol Img 2: 625-628 [Full Text]  
• Steinhubl, S. R., Berger, P. B. (2009). Aspirin following PCI: too much of a good thing?. Eur Heart J 30: 882-884 [Full Text]  
• Waksman, R., Erbel, R., Di Mario, C., Bartunek, J., de Bruyne, B., Eberli, F. R., Erne, P., Haude, M., Horrigan, M., Ilsley, C., Bose, D., Bonnier, H., Koolen, J., Luscher, T. F., Weissman, N. J., on behalf of the PROGRESS-AMS (Clinical Performanc, (2009). Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries. J Am Coll Cardiol Intv 2: 312-320 [Abstract] [Full Text]  
• Shishehbor, M. H., Filby, S. J., Chhatriwalla, A. K., Christofferson, R. D., Jain, A., Kapadia, S. R., Lincoff, A. M., Bhatt, D. L., Ellis, S. G. (2009). Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia. J Am Coll Cardiol Intv 2: 329-336 [Abstract] [Full Text]  
• Russo, R. J., Silva, P. D., Teirstein, P. S., Attubato, M. J., Davidson, C. J., DeFranco, A. C., Fitzgerald, P. J., Goldberg, S. L., Hermiller, J. B., Leon, M. B., Ling, F. S., Lucisano, J. E., Schatz, R. A., Wong, S. C., Weissman, N. J., Zientek, D. M., for the AVID Investigators, (2009). A Randomized Controlled Trial of Angiography Versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement (The AVID Trial). Circ Cardiovasc Interv 2: 113-123 [Abstract] [Full Text]  
• Sourgounis, A., Lipiecki, J., Lo, T. S., Hamon, M. (2009). Coronary Stents and Chronic Anticoagulation. Circulation 119: 1682-1688 [Full Text]  
• Bittl, J. A. (2009). Drug-eluting stents for saphenous vein graft lesions: the limits of evidence.. J Am Coll Cardiol 53: 929-930 [Full Text]  
• Colombo, A., Bramucci, E., Sacca, S., Violini, R., Lettieri, C., Zanini, R., Sheiban, I., Paloscia, L., Grube, E., Schofer, J., Bolognese, L., Orlandi, M., Niccoli, G., Latib, A., Airoldi, F. (2009). Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 119: 71-78 [Abstract] [Full Text]  
• Chhatriwalla, A. K., Bhatt, D. L. (2008). Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely. Circ Cardiovasc Interv 1: 217-225 [Full Text]  
• Shih, C., Berliner, E. (2008). Diffusion Of New Technology And Payment Policies: Coronary Stents. Health Aff (Millwood) 27: 1566-1576 [Abstract] [Full Text]  
• Firth, B. G., Cooper, L. M., Fearn, S. (2008). The Appropriate Role Of Cost-Effectiveness In Determining Device Coverage: A Case Study Of Drug-Eluting Stents. Health Aff (Millwood) 27: 1577-1586 [Abstract] [Full Text]  
• Niemela, K. O. (2008). Biodegradable coating for drug-eluting stents--more than a facelift?. Eur Heart J 29: 1930-1931 [Full Text]  
• Holmes, D. R. Jr, Williams, D. O. (2008). Catheter-Based Treatment of Coronary Artery Disease: Past, Present, and Future. Circ Cardiovasc Interv 1: 60-73 [Abstract] [Full Text]  
• Newsome, L. T., Kutcher, M. A., Royster, R. L. (2008). Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesth. Analg. 107: 552-569 [Abstract] [Full Text]  
• Yao, E.-H., Fukuda, N., Ueno, T., Matsuda, H., Matsumoto, K., Nagase, H., Matsumoto, Y., Takasaka, A., Serie, K., Sugiyama, H., Sawamura, T. (2008). Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Attenuates Restenosis of the Artery After Injury. Hypertension 52: 86-92 [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., Steg, G., Guyatt, G. H., Goodman, S. G. (2008). Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S [Abstract] [Full Text]  
• Bhatt, S. H, Hauser, T. H (2008). Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis. The Annals of Pharmacotherapy 42: 708-712 [Abstract] [Full Text]  
• Mauri, L., Normand, S.-L. T. (2008). Studies of Drug-Eluting Stents: To Each His Own?. Circulation 117: 2047-2050 [Full Text]  
• Hannan, E. L., Racz, M., Holmes, D. R., Walford, G., Sharma, S., Katz, S., Jones, R. H., King, S. B. III (2008). Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents. Circulation 117: 2071-2078 [Abstract] [Full Text]  
• Bonello, L., Camoin-Jau, L., Arques, S., Boyer, C., Panagides, D., Wittenberg, O., Simeoni, M.-C., Barragan, P., Dignat-George, F., Paganelli, F. (2008). Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study. J Am Coll Cardiol 51: 1404-1411 [Abstract] [Full Text]  
• Doyle, B. J., Ting, H. H., Bell, M. R., Lennon, R. J., Mathew, V., Singh, M., Holmes, D. R., Rihal, C. S. (2008). Major Femoral Bleeding Complications After Percutaneous Coronary Intervention: Incidence, Predictors, and Impact on Long-Term Survival Among 17,901 Patients Treated at the Mayo Clinic From 1994 to 2005. J Am Coll Cardiol Intv 1: 202-209 [Abstract] [Full Text]  
• Chadjichristos, C. E., Morel, S., Derouette, J.-P., Sutter, E., Roth, I., Brisset, A. C., Bochaton-Piallat, M.-L., Kwak, B. R. (2008). Targeting Connexin 43 Prevents Platelet-Derived Growth Factor-BB-Induced Phenotypic Change in Porcine Coronary Artery Smooth Muscle Cells. Circ. Res. 102: 653-660 [Abstract] [Full Text]  
• Pinto Slottow, T. L., Waksman, R. (2008). Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent. Circulation 117: 1603-1608 [Full Text]  
• Altin, T., Berkalp, B., Ozdol, C., Akyurek, O., Sayin, T., Kervancioglu, C., Oral, D., Erol, C. (2008). Angiographic Restenosis in Ephesos Coronary Stents: Experience From a Large Medical Center in Ankara, Turkey. ANGIOLOGY 59: 47-51 [Abstract]  
• Brown, M. L., Sundt, T. M. III, Gersh, B. J. (2008). Indications for Revascularization. Card Surg Adult 3: 551-572 [Full Text]  
• Wilson, J. M., Willerson, J. T. (2008). Myocardial Revascularization with Percutaneous Devices. Card Surg Adult 3: 573-598 [Full Text]  
• Jensen, L. O., Thayssen, P., Thuesen, L., Hansen, H. S., Lassen, J. F., Kelbaek, H., Junker, A., Hansen, K. N., Boetker, H. E., Krusell, L. R., Pedersen, K. E. (2007). Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention. Circulation 116: 2802-2808 [Abstract] [Full Text]  
• Williams, D. O., Abbott, J. D. (2007). Et Tu, Bare Metal Stent?. Circulation 116: 2363-2365 [Full Text]  
• Bode, C. (2007). Introduction. Eur Heart J Suppl 9: D1-D2 [Full Text]  
• Bode, C., Zehender, M. (2007). The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Eur Heart J Suppl 9: D10-D19 [Abstract] [Full Text]  
• Fiorella, D., Woo, H. H. (2007). Emerging Endovascular Therapies for Symptomatic Intracranial Atherosclerotic Disease. Stroke 38: 2391-2396 [Full Text]  
• Katritsis, D. G., Ioannidis, J. P.A., Wharton, T. P. Jr., Umans, V. A., Peels, H. O., Shah, A. P., Shavelle, D. M., French, W. J., De Servi, S., Kiat, H., Nagajothi, N., Velazquez-Cecena, J.-L. E., Khosla, S., Mak, K.-H., Boden, W. E., Teo, K. K., Weintraub, W. S., the COURAGE Trial Investigators, (2007). PCI for Stable Coronary Disease. NEJM 357: 414-418 [Full Text]  
• Cademartiri, F., Schuijf, J. D., Pugliese, F., Mollet, N. R., Jukema, J. W., Maffei, E., Kroft, L. J., Palumbo, A., Ardissino, D., Serruys, P. W., Krestin, G. P., Van der Wall, E. E., de Feyter, P. J., Bax, J. J. (2007). Usefulness of 64-Slice Multislice Computed Tomography Coronary Angiography to Assess In-Stent Restenosis. J Am Coll Cardiol 49: 2204-2210 [Abstract] [Full Text]  
• Wong, S. H, Wan, S., Underwood, M. J (2007). Myocardial Revascularization: Surgery or Stenting?. Asian Cardiovasc. Thorac. Ann. 15: 264-269 [Abstract] [Full Text]  
• Jaumdally, R., Varma, C., Macfadyen, R. J., Lip, G. Y.H. (2007). Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. Eur Heart J 28: 929-940 [Abstract] [Full Text]  
• Tiroch, K., Koch, W., von Beckerath, N., Kastrati, A., Schomig, A. (2007). Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J 28: 968-973 [Abstract] [Full Text]  
• Ali, Z. A., Alp, N. J., Lupton, H., Arnold, N., Bannister, T., Hu, Y., Mussa, S., Wheatcroft, M., Greaves, D. R., Gunn, J., Channon, K. M. (2007). Increased In-Stent Stenosis in ApoE Knockout Mice: Insights from a Novel Mouse Model of Balloon Angioplasty and Stenting. Arterioscler. Thromb. Vasc. Bio. 27: 833-840 [Abstract] [Full Text]  
• Camenzind, E., Steg, P. G., Wijns, W. (2007). A Cause for Concern. Circulation 115: 1440-1455 [Full Text]  
• Mauri, L., Hsieh, W.-h., Massaro, J. M., Ho, K. K.L., D'Agostino, R., Cutlip, D. E. (2007). Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. NEJM 356: 1020-1029 [Abstract] [Full Text]  
• Luscher, T. F., Steffel, J., Eberli, F. R., Joner, M., Nakazawa, G., Tanner, F. C., Virmani, R. (2007). Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications. Circulation 115: 1051-1058 [Abstract] [Full Text]  
• Denvir, M A, Lee, A J, Rysdale, J, Prescott, R J, Eteiba, H, Starkey, I R, Pell, J P, Walker, A (2007). Effects of changing clinical practice on costs and outcomes of percutaneous coronary intervention between 1998 and 2002. Heart 93: 195-199 [Abstract] [Full Text]  
• Tang, L., Chen, X., Tang, S., LaLonde, T., Gardin, J. M (2007). Granulation encapsulated stent: a new therapeutic approach for vascular implantation. Heart 93: 238-243 [Abstract] [Full Text]  
• Weisfeldt, M. L., Zieman, S. J. (2007). Advances In The Prevention And Treatment Of Cardiovascular Disease. Health Aff (Millwood) 26: 25-37 [Abstract] [Full Text]  
• Park, D.-W., Hong, M.-K., Mintz, G. S., Lee, C. W., Song, J.-M., Han, K.-H., Kang, D.-H., Cheong, S.-S., Song, J.-K., Kim, J.-J., Weissman, N. J., Park, S.-W., Park, S.-J. (2006). Two-Year Follow-Up of the Quantitative Angiographic and Volumetric Intravascular Ultrasound Analysis After Nonpolymeric Paclitaxel-Eluting Stent Implantation: Late "Catch-Up" Phenomenon From ASPECT Study. J Am Coll Cardiol 48: 2432-2439 [Abstract] [Full Text]  
• Ashley, E. A., Ferrara, R., King, J. Y., Vailaya, A., Kuchinsky, A., He, X., Byers, B., Gerckens, U., Oblin, S., Tsalenko, A., Soito, A., Spin, J. M., Tabibiazar, R., Connolly, A. J., Simpson, J. B., Grube, E., Quertermous, T. (2006). Network Analysis of Human In-Stent Restenosis. Circulation 114: 2644-2654 [Abstract] [Full Text]  
• Nordmann, A. J., Briel, M., Bucher, H. C. (2006). Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27: 2784-2814 [Abstract] [Full Text]  
• Camenzind, E. (2006). Treatment of In-Stent Restenosis -- Back to the Future?. NEJM 355: 2149-2151 [Full Text]  
• Yan, S.-F., Harja, E., Andrassy, M., Fujita, T., Schmidt, A. M. (2006). Protein Kinase C {beta}/Early Growth Response-1 Pathway: A Key Player in Ischemia, Atherosclerosis, and Restenosis. J Am Coll Cardiol 48: A47-A55 [Abstract] [Full Text]  
• Eisenberg, M. J. (2006). Drug-Eluting Stents: The Price Is Not Right. Circulation 114: 1745-1754 [Full Text]  
• Ilkay, E., Tirikli, L., Ozercan, I., Yavuzkir, M., Karaca, I., Rahman, A., Arslan, N. (2006). Oral Mycophenolate Mofetil Prevents In-Stent Intimal Hyperplasia Without Edge Effect. ANGIOLOGY 57: 577-584 [Abstract]  
• Yokouchi, K., Numaguchi, Y., Kubota, R., Ishii, M., Imai, H., Murakami, R., Ogawa, Y., Kondo, T., Okumura, K., Ingber, D. E., Murohara, T. (2006). l-Caldesmon Regulates Proliferation and Migration of Vascular Smooth Muscle Cells and Inhibits Neointimal Formation After Angioplasty. Arterioscler. Thromb. Vasc. Bio. 26: 2231-2237 [Abstract] [Full Text]  
• Suttorp, M. J., Laarman, G. J., Rahel, B. M., Kelder, J. C., Bosschaert, M. A.R., Kiemeneij, F., ten Berg, J. M., Bal, E. T., Rensing, B. J., Eefting, F. D., Mast, E. G. (2006). Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions. Circulation 114: 921-928 [Abstract] [Full Text]  
• Cin, V. G., Pekdemir, H., Akkus, M. N., Camsari, A., Doven, O., Yenihan, S. (2006). Cutting Balloon Angioplasty for the Treatment of In-Stent Restenosis in Diabetics: A Matched Comparison of 6 Months' Outcome With Conventional Balloon Angioplasty. ANGIOLOGY 57: 445-452 [Abstract]  
• Ozdemir, R., Sezgin, A. T., Barutcu, I., Topal, E., Gullu, H., Acikgoz, N. (2006). Comparison of Direct Stenting Versus Conventional Stent Implantation on Blood Flow in Patients With ST-Segment Elevation Myocardial Infarction. ANGIOLOGY 57: 453-458 [Abstract]  
• Waksman, R, Leitch, I M, Roessler, J, Yazdi, H, Seabron, R, Tio, F, Scott, R W, Grove, R I, Rychnovsky, S, Robinson, B, Pakala, R, Cheneau, E (2006). Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model. Heart 92: 1138-1144 [Abstract] [Full Text]  
• Ong, A. T.L., Serruys, P. W. (2006). Complete Revascularization: Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention. Circulation 114: 249-255 [Full Text]  
• Numaguchi, Y., Sone, T., Okumura, K., Ishii, M., Morita, Y., Kubota, R., Yokouchi, K., Imai, H., Harada, M., Osanai, H., Kondo, T., Murohara, T. (2006). The Impact of the Capability of Circulating Progenitor Cell to Differentiate on Myocardial Salvage in Patients With Primary Acute Myocardial Infarction. Circulation 114: I-114-I-119 [Abstract] [Full Text]  
• Chadjichristos, C. E., Matter, C. M., Roth, I., Sutter, E., Pelli, G., Luscher, T. F., Chanson, M., Kwak, B. R. (2006). Reduced Connexin43 Expression Limits Neointima Formation After Balloon Distension Injury in Hypercholesterolemic Mice. Circulation 113: 2835-2843 [Abstract] [Full Text]  
• Alfonso, F., Perez-Vizcayno, M.-J., Hernandez, R., Bethencourt, A., Marti, V., Lopez-Minguez, J. R., Angel, J., Mantilla, R., Moris, C., Cequier, A., Sabate, M., Escaned, J., Moreno, R., Banuelos, C., Suarez, A., Macaya, C., for the RIBS-II Investigators, (2006). A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial. J Am Coll Cardiol 47: 2152-2160 [Abstract] [Full Text]  
• Krueger, K D, Mitra, A K, DelCore, M G, Hunter, W J III, Agrawal, D K (2006). A comparison of stent-induced stenosis in coronary and peripheral arteries. J. Clin. Pathol. 59: 575-579 [Abstract] [Full Text]  
• Serruys, P. W. (2006). Fourth Annual American College of Cardiology International Lecture: A Journey in the Interventional Field. J Am Coll Cardiol 47: 1754-1768 [Full Text]  
• Haan, C. K., O'Brien, S., Edwards, F. H., Peterson, E. D., Ferguson, T. B. (2006). Trends in emergency coronary artery bypass grafting after percutaneous coronary intervention, 1994-2003.. Ann. Thorac. Surg. 81: 1658-1665 [Abstract] [Full Text]  
• Roiron, C, Sanchez, P, Bouzamondo, A, Lechat, P, Montalescot, G (2006). Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 92: 641-649 [Abstract] [Full Text]  
• Pugliese, F., Cademartiri, F., van Mieghem, C., Meijboom, W. B., Malagutti, P., Mollet, N. R. A., Martinoli, C., de Feyter, P. J., Krestin, G. P. (2006). Multidetector CT for visualization of coronary stents.. RadioGraphics 26: 887-904 [Abstract] [Full Text]  
• Rodriguez, A. E., Granada, J. F., Rodriguez-Alemparte, M., Vigo, C. F., Delgado, J., Fernandez-Pereira, C., Pocovi, A., Rodriguez-Granillo, A. M., Schulz, D., Raizner, A. E., Palacios, I., O'Neill, W., Kaluza, G. L., Stone, G., for the ORAR II Investigators, (2006). Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 47: 1522-1529 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Teirstein, P., Satler, L., Sketch, M., O'Malley, J., Popma, J. J., Kuntz, R. E., Fitzgerald, P. J., Wang, H., Caramanica, E., Cohen, S. A., for the SISR Investigators, (2006). Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial. JAMA 295: 1264-1273 [Abstract] [Full Text]  
• Kim, W., Jeong, M. H., Kim, K. H., Sohn, I. S., Hong, Y. J., Park, H. W., Kim, J. H., Ahn, Y. K., Cho, J. G., Park, J. C., Cho, D. L., Kang, J. C. (2006). The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction. J Am Coll Cardiol 47: 933-938 [Abstract] [Full Text]  
• Mitra, A K, Agrawal, D K (2006). In stent restenosis: bane of the stent era.. J. Clin. Pathol. 59: 232-239 [Abstract] [Full Text]  
• Serruys, P. W., Kutryk, M. J.B., Ong, A. T.L. (2006). Coronary-Artery Stents. NEJM 354: 483-495 [Full Text]  
• Lee, C.-H., Tan, H.-C., Lim, Y.-T. (2006). Update on Drug-Eluting Stents for Prevention of Restenosis. Asian Cardiovasc. Thorac. Ann. 14: 75-82 [Abstract] [Full Text]  
• Mehilli, J., Dibra, A., Kastrati, A., Pache, J., Dirschinger, J., Schomig, A., for the Intracoronary Drug-Eluting Stenting to Abr, (2006). Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27: 260-266 [Abstract] [Full Text]  
• Batyraliev, T. A., Pershukov, I. V., Niyazova-Karben, Z. A., Karaus, A., Calenici, O., Guler, N., Eryonucu, B., Temamogullari, A., Ozgul, S., Akgul, F., Sengul, H., Dogru, O., Demirbas, O., Timoshin, I. S., Gaigukov, A. V., Petrakova, L. N., Peresypko, M. K., Sidorenko, B. A., International Invasive Cardiology Research Group, (2006). Current Role of Laser Angioplasty of Restenotic Coronary Stents. ANGIOLOGY 57: 21-32 [Abstract]  
• Alvarez, W. Jr, Kapur, N. K. (2005). Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis. Journal of Pharmacy Practice 18: 461-478 [Abstract]  
• Dawkins, K D, Gershlick, T, de Belder, M, Chauhan, A, Venn, G, Schofield, P, Smith, D, Watkins, J, Gray, H H, Joint Working Group on Percutaneous Coronary Inter, (2005). Percutaneous coronary intervention: recommendations for good practice and training. Heart 91: vi1-vi27 [Abstract] [Full Text]  
• Pislaru, S., Simari, R. D. (2005). The Translation of Transcription. Circ. Res. 97: 1083-1084 [Full Text]  
• De Luca, G., Suryapranata, H., Gregorio, G., Lange, H., Chiariello, M. (2005). Homocysteine and Its Effects on In-Stent Restenosis. Circulation 112: e307-e311 [Full Text]  
• Nawarskas, J. J., Osborn, L. A. (2005). Paclitaxel-eluting stents in coronary artery disease. Am J Health Syst Pharm 62: 2241-2251 [Abstract] [Full Text]  
• Douglas, J. S. Jr, Holmes, D. R. Jr, Kereiakes, D. J., Grines, C. L., Block, E., Ghazzal, Z. M.B., Morris, D. C., Liberman, H., Parker, K., Jurkovitz, C., Murrah, N., Foster, J., Hyde, P., Mancini, G.B. J., Weintraub, W. S., for the Cilostazol for Restenosis Trial (CREST) In, (2005). Coronary Stent Restenosis in Patients Treated With Cilostazol. Circulation 112: 2826-2832 [Abstract] [Full Text]  
• Stone, G. W., Kandzari, D. E., Mehran, R., Colombo, A., Schwartz, R. S., Bailey, S., Moussa, I., Teirstein, P. S., Dangas, G., Baim, D. S., Selmon, M., Strauss, B. H., Tamai, H., Suzuki, T., Mitsudo, K., Katoh, O., Cox, D. A., Hoye, A., Mintz, G. S., Grube, E., Cannon, L. A., Reifart, N. J., Reisman, M., Abizaid, A., Moses, J. W., Leon, M. B., Serruys, P. W. (2005). Percutaneous Recanalization of Chronically Occluded Coronary Arteries: A Consensus Document: Part I. Circulation 112: 2364-2372 [Full Text]  
• Inami, N., Nomura, S., Kajiura, T., Yamada, K., Nakamori, H., Takahashi, N., Tsuda, N., Fukuhara, S., Iwasaka, T. (2005). Significance of {alpha}IIb{beta}3 in Subacute Stent ThrombosisAfter Percutaneous Coronary Intervention. CLIN APPL THROMB HEMOST 11: 455-459 [Abstract]  
• Valgimigli, M., Percoco, G., Cicchitelli, G., Campo, G., Gardini, E., Pellegrino, L., Malagutti, P., Giretti, C., Ferrari, R. (2005). New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Eur Heart J Suppl 7: K31-K35 [Abstract] [Full Text]  
• Alfonso, F., Auge, J. M., Zueco, J., Bethencourt, A., Lopez-Minguez, J. R., Hernandez, J. M., Bullones, J. A., Calvo, I., Esplugas, E., Perez-Vizcayno, M. J., Moreno, R., Fernandez, C., Hernandez, R., Gama-Ribeiro, V., for the RIBS Investigators, (2005). Long-Term Results (Three to Five Years) of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Randomized Study. J Am Coll Cardiol 46: 756-760 [Abstract] [Full Text]  
• Zimarino, M., Calafiore, A. M., De Caterina, R. (2005). Complete myocardial revascularization: between myth and reality. Eur Heart J 26: 1824-1830 [Abstract] [Full Text]